Disclaimer

This Web site has been created solely for the purpose of providing information about services available from Richmond Pharmacology (RP). The site has been compiled in good faith from information available at the time and is therefore subject to change at any time and without notification.

Due to web security any ideas and or information sent to RP via this Web site will be deemed not to be confidential and by sending information, you are granting RP unrestricted and irrevocable licence to use, reproduce, display, perform, modify, transmit and distribute. However RP will not release your name or otherwise publicise the fact that information was sent unless RP obtains your permission to do so or if RP is required to do so by law.

Please note that RP does not endorse any other Web sites accessed via this site or accepts any responsibility for the content or accuracy of information contained on that site. In no event will RP be liable to any party for any damages arising from any use of or access to this Web site.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Making gains in drug development

September 2, 2021
Keith Berelowitz outlines the innovations in the design and delivery of clinical trials
Read more

Inclisirin hailed as a 'gamechanger' gains approval for NHS patients

September 2, 2021
This novel therapeutic drug has potential to impact millions at risk of heart attack and stroke.
Read more

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more